BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 37294843)

  • 1. Same-day testing with initiation of antiretroviral therapy or tuberculosis treatment versus standard care for persons presenting with tuberculosis symptoms at HIV diagnosis: A randomized open-label trial from Haiti.
    Dorvil N; Rivera VR; Riviere C; Berman R; Severe P; Bang H; Lavoile K; Devieux JG; Faustin M; Saintyl G; Mendicuti MD; Pierre S; Apollon A; Dumond E; Forestal GPL; Rouzier V; Marcelin A; McNairy ML; Walsh KF; Dupnik K; Reif LK; Byrne AL; Bousleiman S; Orvis E; Joseph P; Cremieux PY; Pape JW; Koenig SP
    PLoS Med; 2023 Jun; 20(6):e1004246. PubMed ID: 37294843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial.
    Koenig SP; Dorvil N; Dévieux JG; Hedt-Gauthier BL; Riviere C; Faustin M; Lavoile K; Perodin C; Apollon A; Duverger L; McNairy ML; Hennessey KA; Souroutzidis A; Cremieux PY; Severe P; Pape JW
    PLoS Med; 2017 Jul; 14(7):e1002357. PubMed ID: 28742880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical algorithm for same-day HIV treatment initiation in settings with high TB symptom prevalence in South Africa: The SLATE II individually randomized clinical trial.
    Maskew M; Brennan AT; Fox MP; Vezi L; Venter WDF; Ehrenkranz P; Rosen S
    PLoS Med; 2020 Aug; 17(8):e1003226. PubMed ID: 32853271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Same-day versus rapid ART initiation in HIV-positive individuals presenting with symptoms of tuberculosis: Protocol for an open-label randomized non-inferiority trial in Lesotho and Malawi.
    Gerber F; Semphere R; Lukau B; Mahlatsi P; Mtenga T; Lee T; Kohler M; Glass TR; Amstutz A; Molatelle M; MacPherson P; Marake NB; Nliwasa M; Ayakaka I; Burke R; Labhardt N
    PLoS One; 2024; 19(2):e0288944. PubMed ID: 38330045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial.
    Rosen S; Maskew M; Fox MP; Nyoni C; Mongwenyana C; Malete G; Sanne I; Bokaba D; Sauls C; Rohr J; Long L
    PLoS Med; 2016 May; 13(5):e1002015. PubMed ID: 27163694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
    De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B;
    Lancet Infect Dis; 2021 Jun; 21(6):813-822. PubMed ID: 33667406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simplified clinical algorithm for identifying patients eligible for same-day HIV treatment initiation (SLATE): Results from an individually randomized trial in South Africa and Kenya.
    Rosen S; Maskew M; Larson BA; Brennan AT; Tsikhutsu I; Fox MP; Vezi L; Bii M; Venter WDF
    PLoS Med; 2019 Sep; 16(9):e1002912. PubMed ID: 31525187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved simplified clinical algorithm for identifying patients eligible for immediate initiation of antiretroviral therapy for HIV (SLATE II): protocol for a randomized evaluation.
    Rosen S; Maskew M; Brennan AT; Fox MP; Vezi L; Ehrenkranz PD; Venter WDF
    Trials; 2018 Oct; 19(1):548. PubMed ID: 30305142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial.
    Labhardt ND; Ringera I; Lejone TI; Klimkait T; Muhairwe J; Amstutz A; Glass TR
    JAMA; 2018 Mar; 319(11):1103-1112. PubMed ID: 29509839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome after early initiation of antiretroviral therapy in a randomized clinical trial.
    Laureillard D; Marcy O; Madec Y; Chea S; Chan S; Borand L; Fernandez M; Prak N; Kim C; Dim B; Nerrienet E; Sok T; Delfraissy JF; Goldfeld AE; Blanc FX;
    AIDS; 2013 Oct; 27(16):2577-86. PubMed ID: 24096631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.
    Amogne W; Aderaye G; Habtewold A; Yimer G; Makonnen E; Worku A; Sonnerborg A; Aklillu E; Lindquist L
    PLoS One; 2015; 10(5):e0122587. PubMed ID: 25966339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, SAfety/tolerability, and EFficacy of high-dose RIFampicin in tuberculosis-HIV co-infected patients on efavirenz- or dolutegravir-based antiretroviral therapy: study protocol for an open-label, phase II clinical trial (SAEFRIF).
    Nabisere R; Musaazi J; Denti P; Aber F; Lamorde M; Dooley KE; Aarnoutse R; Sloan DJ; Sekaggya-Wiltshire C
    Trials; 2020 Feb; 21(1):181. PubMed ID: 32054536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Algorithm-guided empirical tuberculosis treatment for people with advanced HIV (TB Fast Track): an open-label, cluster-randomised trial.
    Grant AD; Charalambous S; Tlali M; Karat AS; Dorman SE; Hoffmann CJ; Johnson S; Vassall A; Churchyard GJ; Fielding KL
    Lancet HIV; 2020 Jan; 7(1):e27-e37. PubMed ID: 31727580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nevirapine- versus Efavirenz-based antiretroviral therapy regimens in antiretroviral-naive patients with HIV and Tuberculosis infections in India: a multi-centre study.
    Sinha S; Gupta K; Tripathy S; Dhooria S; Ranjan S; Pandey RM
    BMC Infect Dis; 2017 Dec; 17(1):761. PubMed ID: 29228918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Same-day antiretroviral therapy (ART) initiation in pregnancy is not associated with viral suppression or engagement in care: A cohort study.
    Langwenya N; Phillips TK; Brittain K; Zerbe A; Abrams EJ; Myer L
    J Int AIDS Soc; 2018 Jun; 21(6):e25133. PubMed ID: 29939483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
    Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
    Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of active tuberculosis among people living with HIV receiving long-term antiretroviral therapy in high TB/HIV burden settings in Thailand: implication for tuberculosis preventive therapy.
    Suwanpimolkul G; Gatechompol S; Kawkitinarong K; Ueaphongsukkit T; Sophonphan J; Siriyakorn N; Jirajariyavej S; Khusuwan S; Panarat P; Wannalerdsakun S; Saetiew N; Chayangsu S; Wiwatrojanagul S; Noopetch P; Danpornprasert P; Mekviwattanawong S; Fujitnirun C; Lertpiriyasuwat C; Han WM; Kerr SJ; Ruxrungtham K; Avihingsanon A;
    J Int AIDS Soc; 2022 Apr; 25(4):e25900. PubMed ID: 35384317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis treatment intermittency in the continuation phase and mortality in HIV-positive persons receiving antiretroviral therapy.
    Crabtree-Ramirez B; Jenkins CA; Shepherd BE; Jayathilake K; Veloso VG; Carriquiry G; Gotuzzo E; Cortes CP; Padgett D; McGowan C; Sierra-Madero J; Koenig S; Pape JW; Sterling TR;
    BMC Infect Dis; 2022 Apr; 22(1):341. PubMed ID: 35382770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.
    Ciaffi L; Koulla-Shiro S; Sawadogo AB; Ndour CT; Eymard-Duvernay S; Mbouyap PR; Ayangma L; Zoungrana J; Gueye NFN; Diallo M; Izard S; Bado G; Kane CT; Aghokeng AF; Peeters M; Girard PM; Le Moing V; Reynes J; Delaporte E;
    Lancet HIV; 2017 Sep; 4(9):e384-e392. PubMed ID: 28566227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.
    Havlir DV; Kendall MA; Ive P; Kumwenda J; Swindells S; Qasba SS; Luetkemeyer AF; Hogg E; Rooney JF; Wu X; Hosseinipour MC; Lalloo U; Veloso VG; Some FF; Kumarasamy N; Padayatchi N; Santos BR; Reid S; Hakim J; Mohapi L; Mugyenyi P; Sanchez J; Lama JR; Pape JW; Sanchez A; Asmelash A; Moko E; Sawe F; Andersen J; Sanne I;
    N Engl J Med; 2011 Oct; 365(16):1482-91. PubMed ID: 22010914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.